Evofem Biosciences (EVFM) investor relations material

Executive summary

• Commercial portfolio includes PHEXX (non-hormonal contraceptive gel) and SOLOSEC (single-dose antimicrobial for BV and trichomoniasis), with SOLOSEC acquired in July 2024 and relaunched in November 2024.

• Net product sales for Q1 2026 were $899K, up 6% year-over-year, driven by higher WAC for PHEXX and increased SOLOSEC sales, partially offset by lower PHEXX volume.

• Company faces significant liquidity challenges, with a $72.7M working capital deficit and $902.9M accumulated deficit as of March 31, 2026.

• Management has concluded there is substantial doubt about the ability to continue as a going concern without additional funding.

Financial highlights

• Net loss for Q1 2026 was $5.5M, compared to net income of $1.0M in Q1 2025, primarily due to the absence of one-time R&D expense reductions seen in the prior year.

• Cost of goods sold increased 12% to $410K, mainly due to write-off of expired raw materials.

• Research and development expenses were $518K, versus a negative $5.0M in Q1 2025, reflecting a prior period one-time reduction from trade payable settlements.

• Selling and marketing expenses decreased 20% to $2.1M, reflecting lower personnel and distribution costs.

• General and administrative expenses were flat at $2.4M.

• Cash and cash equivalents at quarter-end were $2.4M, including $0.9M restricted.

Outlook and guidance

• Management plans to focus on top-line growth, maintain a lean cost structure, and seek additional funding through product sales, restructuring payables, and potential equity or debt financings.

• Strategic priorities include expanding PHEXX and SOLOSEC access, pursuing ex-U.S. partnerships, and exploring new market opportunities.